Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.
John Dunlop, Karen L Marquis, H K Lim, Louis Leung, John Kao, Cynthia Cheesman, Sharon Rosenzweig-Lipson
Author Information
John Dunlop: Discovery Neuroscience, Wyeth Research, Princeton, NJ 08543, USA. dunlopj@wyeth.com
The 5-HT(2C) receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery. Here we review the pharmacological, pharmacokinetic and toxicological profile of WAY-163909 {(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole}, a novel 5-HT(2C) receptor selective agonist. Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression.
Neuropharmacology. 1999 Aug;38(8):1083-152
[PMID: 10462127 ]
Br J Pharmacol. 2000 Jul;130(6):1305-14
[PMID: 10903970 ]
Bioorg Med Chem Lett. 2000 Sep 4;10(17):1991-4
[PMID: 10987434 ]
Psychopharmacology (Berl). 1979 Nov;66(2):207-8
[PMID: 119266 ]
Psychopharmacology (Berl). 2003 May;167(3):274-80
[PMID: 12690422 ]
Eur J Pharmacol. 2004 Jan 1;483(1):37-43
[PMID: 14709324 ]
Pharmacol Biochem Behav. 2004 Jan;77(1):69-75
[PMID: 14724043 ]
Bioorg Med Chem Lett. 2004 May 17;14(10):2603-7
[PMID: 15109661 ]
Brain Res. 2004 Jun 18;1011(2):221-7
[PMID: 15157808 ]
Curr Pharm Des. 2005;11(2):171-203
[PMID: 15638757 ]
J Pharmacol Exp Ther. 2005 May;313(2):862-9
[PMID: 15705738 ]
Brain Res. 2006 Feb 16;1073-1074:240-51
[PMID: 16430874 ]
Psychopharmacology (Berl). 1991;105(3):340-6
[PMID: 1665919 ]
J Pharmacol Exp Ther. 2007 Jan;320(1):486-96
[PMID: 17038512 ]
Br J Pharmacol. 1991 Aug;103(4):2016-20
[PMID: 1912990 ]
Trends Pharmacol Sci. 1989 Aug;10(8):307-9
[PMID: 2686127 ]
Psychopharmacology (Berl). 1988;96(1):93-100
[PMID: 2906446 ]
Naunyn Schmiedebergs Arch Pharmacol. 1979 Aug;308(2):159-63
[PMID: 503247 ]
Pharmacol Ther. 1995 Apr;66(1):17-37
[PMID: 7630928 ]
Nature. 1995 Apr 6;374(6522):542-6
[PMID: 7700379 ]
Psychopharmacology (Berl). 1994 Sep;116(1):120-2
[PMID: 7862925 ]
Psychopharmacology (Berl). 1993;112(2-3):195-8
[PMID: 7871019 ]
Neuropharmacology. 1994 Mar-Apr;33(3-4):457-65
[PMID: 7984284 ]
Psychopharmacology (Berl). 1995 Sep;121(1):66-72
[PMID: 8539342 ]
Eur J Pharmacol. 1997 Apr 23;325(1):9-12
[PMID: 9151932 ]
J Med Chem. 1997 Aug 15;40(17):2762-9
[PMID: 9276022 ]
Pharmacol Ther. 1997;74(3):299-316
[PMID: 9352586 ]
Psychopharmacology (Berl). 1997 Oct;133(3):309-12
[PMID: 9361339 ]
Eur J Pharmacol. 1998 Jul 3;352(1):23-8
[PMID: 9718263 ]
Eur J Pharmacol. 1999 Jan 8;364(2-3):123-32
[PMID: 9932714 ]
Animals
Antidepressive Agents
Antipsychotic Agents
Azepines
Eating
Humans
Indoles
Serotonin 5-HT2 Receptor Agonists
1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta(b)(1,4)diazepino(6,7,1hj)indole
Antidepressive Agents
Antipsychotic Agents
Azepines
Indoles
Serotonin 5-HT2 Receptor Agonists
